Overview

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib. Glutamine may help prevent peripheral neuropathy in patients receiving chemotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Beth Faiman
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bortezomib